A citation-based method for searching scientific literature

Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco, Huiling Pei, Bruce Bode. Lancet 2012
Times Cited: 239







List of co-cited articles
632 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
147
53

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
236
43


Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
225
36


Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
238
30

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
116
29

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
114
28



Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
Ib Jonassen, Svend Havelund, Thomas Hoeg-Jensen, Dorte Bjerre Steensgaard, Per-Olof Wahlund, Ulla Ribel. Pharm Res 2012
273
24

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
225
23



Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Kåre I Birkeland, Philip D Home, Ulrich Wendisch, Robert E Ratner, Thue Johansen, Lars A Endahl, Karsten Lyby, Johan H Jendle, Anthony P Roberts, J Hans DeVries,[...]. Diabetes Care 2011
126
22

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Carol Wysham, Anuj Bhargava, Louis Chaykin, Raymond de la Rosa, Yehuda Handelsman, Lone N Troelsen, Kajsa Kvist, Paul Norwood. JAMA 2017
140
19

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Tim Heise, Leszek Nosek, Birgitte Biilmann Rønn, Lars Endahl, Lutz Heinemann, Christoph Kapitza, Eberhard Draeger. Diabetes 2004
409
18




Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
75
21

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
78
20


New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
181
15

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
290
15

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Irl B Hirsch, Bruce Bode, Jean-Pierre Courreges, Patrik Dykiel, Edward Franek, Kjeld Hermansen, Allen King, Henriette Mersebach, Melanie Davies. Diabetes Care 2012
56
25

Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Tim Heise, Marianne Nørskov, Leszek Nosek, Kadriye Kaplan, Susanne Famulla, Hanne L Haahr. Diabetes Obes Metab 2017
72
19


Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
M Monami, N Marchionni, E Mannucci. Diabetes Obes Metab 2009
117
13

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
H W Rodbard, B Cariou, B Zinman, Y Handelsman, A Philis-Tsimikas, T V Skjøth, A Rana, C Mathieu. Diabet Med 2013
64
18



Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus.
Yoshiki Kusunoki, Tomoyuki Katsuno, Kana Miyakoshi, Takashi Ikawa, Rie Nakae, Fumihiro Ochi, Masaru Tokuda, Takafumi Akagami, Kazuki Murai, Masayuki Miuchi,[...]. Diabetes Ther 2013
21
57

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Stefan Korsatko, Sigrid Deller, Gerd Koehler, Julia K Mader, Katharina Neubauer, Charlotte L Adrian, Henrik Thomsen, Hanne Haahr, Thomas R Pieber. Clin Drug Investig 2013
63
19

The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
Svend Havelund, Anne Plum, Ulla Ribel, Ib Jonassen, Aage Vølund, Jan Markussen, Peter Kurtzhals. Pharm Res 2004
268
11


Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
77
14

Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Francesca Porcellati, Paolo Rossetti, Natalia Ricci Busciantella, Stefania Marzotti, Paola Lucidi, Steven Luzio, David R Owens, Geremia B Bolli, Carmine G Fanelli. Diabetes Care 2007
149
11

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
A Steinstraesser, R Schmidt, K Bergmann, R Dahmen, R H A Becker. Diabetes Obes Metab 2014
64
17

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
11

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
Nandu Thalange, Larry Deeb, Violeta Iotova, Tomoyuki Kawamura, Georgeanna Klingensmith, Areti Philotheou, Janet Silverstein, Stefano Tumini, Ann-Marie Ocampo Francisco, Ona Kinduryte,[...]. Pediatr Diabetes 2015
39
28




Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Bernard Zinman, Greg Fulcher, Paturi V Rao, Nihal Thomas, Lars A Endahl, Thue Johansen, Rebecka Lindh, Andrew Lewin, Julio Rosenstock, Michel Pinget,[...]. Lancet 2011
87
10



A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Johannes Plank, Manfred Bodenlenz, Frank Sinner, Christoph Magnes, Evelyn Görzer, Werner Regittnig, Lars A Endahl, Eberhard Draeger, Milan Zdravkovic, Thomas R Pieber. Diabetes Care 2005
199
9


Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
Ulrik Pedersen-Bjergaard, Peter Lommer Kristensen, Henning Beck-Nielsen, Kirsten Nørgaard, Hans Perrild, Jens Sandahl Christiansen, Tonny Jensen, Philip Hougaard, Hans-Henrik Parving, Birger Thorsteinsson,[...]. Lancet Diabetes Endocrinol 2014
60
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.